Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1821-1840 of 2,251 trials

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Crizotinib for Children with Severe Type 2 Neurofibromatosis

We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.

Neurofibromatosis Type 21-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplant in Children: Prolonged-Release Tacrolimus Study

We are studying a new form of tacrolimus for children who have undergone kidney transplantation. The goal is to see if it works as well and is as safe as the current version used.

Caucasian Pediatric Kidney Transplant Recipients1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

Gastroenteropancreatic and Thoracic Neuroendocrine TumorEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesEndocrinologyOncology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Status Epilepticus Treatment in Elderly Patients

We are investigating a new treatment for established status epilepticus in older adults. This study aims to provide evidence on how effective this treatment is for this vulnerable population.

Status Epilepticus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Stroke Care: HOPE Study on Blood Pressure Management

We are comparing standard blood pressure management to a personalized approach after mechanical thrombectomy for acute ischemic stroke patients. The goal is to see which method better supports recovery and brain health.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Ovarian Cancer: NIraparib and Dostarlimab Study

We are testing a new treatment combination for patients with recurrent ovarian cancer who cannot have platinum therapy. The study aims to see if this combination helps patients live longer compared to standard chemotherapy.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

High-Risk MelanomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Bronchopulmonary Dysplasia: Stem Cell Treatment for Preterm Infants

We are studying the safety of umbilical cord stem cells in preterm babies with bronchopulmonary dysplasia. This research aims to see if the treatment can help improve their lung health and overall development.

Bronchopulmonary Dysplasia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPediatricsPulmonology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Hepatocellular Carcinoma: NMS-01940153E and Atezolizumab Study

We are studying a new treatment combination for adults with unresectable hepatocellular carcinoma who have been treated with other anti-cancer medicines. The goal is to see how well this combination works and its safety compared to existing options.

Unresectable Hepatocellular CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesHepatologyOncology

Hemophilia A: Innovative Treatment Approaches for Patients with Inhibitors

We are exploring various treatment methods for individuals with Hemophilia A who have inhibitors. The goal is to see how well these treatments reduce bleeding and improve health outcomes.

Hemophilia A>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematology